Prevalence and outcome of retinopathy of prematurity in preterm infants, with low birth weight at KMCH, Tamil Nadu, India

R. Nikhil, K. Rajendran, Bala Krishnan


Background: Premature infants have avascular or incompletely vascularized retina at birth and ROP evolves over 4-5 weeks after birth. The aim of this study is to know the prevalence of retinopathy of prematurity in preterm infants, with birth weight ≤ 1500 grams and/or gestational age ≤32 weeks in a tertiary care center.

Methods: The study was conducted in Kovai Medical Centre and Hospital Coimbatore in 2016. The sample size is 95 babies. All preterm infants admitted with a birth weight of ≤1500 grams and/or ≤ 32 weeks of gestation and baby those at risk of ROP.

Results: 95 babies have enrolled during the study period of which 78 babies fulfilled the inclusion criteria and completed this prospective study.12 babies could not complete the follow-up protocol and 5 babies died before full vascularization of the retina. 78 babies who fulfilled the inclusion criteria were screened and 15 babies were found to have ROP. The prevalence of ROP in this study is 19.2%.

Conclusions: Among the preventable causes of blindness in children, ROP figures very high on the agenda. Low birth weight and gestational age were found to be the most important risk factors for the development of ROP.


Low birth weight, Oxygen therapy, Prematurity in preterm infant, Retinopathy

Full Text:



Ahmed MA, Duncan M, Kent A, NICUS Group. Incidence of retinopathy of prematurity requiring treatment in infants born greater than 30 weeks’ gestation and with a birthweight greater than 1250 g from 1998 to 2002: A regional study. J Paediatr Child Health. 2006;42(6):337-40.

Amer M, Jafri WH, Nizami AM, Shomrani AI, Al-Dabaan AA, Rashid K. Retinopathy of prematurity: are we missing any infant with retinopathy of prematurity? Br J Ophthalmol 2012;96(8):1052-5.

Austeng D, Kallen KB, Ewald UW, Jakobsson PG, Holmström GE. Incidence of retinopathy of prematurity in infants born before 27 weeks’ gestation in Sweden. Arch Ophthalmol 2009;127(10):1315-9.

Binkhathlan AA, Almahmoud LA, Saleh MJ, Srungeri S. Retinopathy of prematurity in Saudi Arabia: incidence, risk factors, and the applicability of current screening criteria. Br J Ophthalmol 2008;92(2):167-9.

Bolton DP, Cross KW. Further observations on the cost of preventing retrolental fibroplasia. Lancet. 1974;1(7855):445-8.

Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach. Med J Austral. 1951;2(2):48-50.

CfRoPC Group. Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome–structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1990;108(10):1408-16.

Charan R, Dogra MR, Gupta A, Narang A. The incidence of retinopathy of prematurity in a neonatal care unit. Indian J Ophthalmol. 1995;43:123-6.

Committee for the classification of retinopathy of prematurity: An international classification of retinopathy of prematurity. Arch Ophthalmol. 1984;102:1130-4.

Crosse VM, Evans PJ. Prevention of retrolental fibroplasia. Arch Ophthalmol.1952;48:83-7.

Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Brit J Ophthalmol. 2012;96(5):614-8.

Darlow BA, Hutchinson JL, Henderson-Smart DJ, Donoghue DA, Simpson JM, Evans NJ. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand Neonatal Network. Pediatr. 2005;115(4):990-6.

Flores-Santos R, Hernandez-Cabrera MA, Henandez-Herrera RJ, Sepúlveda-Cañamar F. Screening for retinopathy of prematurity: results of a 7-year study of underweight newborns. Arch Med Res. 2007;38(4):440-3.

Fortes Filho JB, Eckert GU, Procianoy L, Barros CK, Procianoy RS. Incidence and risk factors for retinopathy of prematurity in very low and in extremely low birth weight infants in a unit-based approach in southern Brazil. Eye. 2009;23(1):25-30.

Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84(2):77-82.

Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics 2005;116(1):15-23.

Gopal L, Sharma T, Ramachandran S, Shanmugasundaram R, Asha V. Retinopathy of prematurity. A study. Indian J Ophthalmol. 1995;43:50-61.

Group crops. Multicenter trial of cryotherapy for retinopathy of prematurity. Three-month outcome. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1990;108(2):195-204.

Gunn DJ, Cartwright DW, Gole GA. The incidence of retinopathy of prematurity in extremely premature infants over an 18-year period. Clin Exp Ophthalmol. 2012;40(1):93-9.

Jakuskiene R, Vollmer B, Safaris V, Daugeliene D. Neonatal outcomes of very preterm infants admitted to a tertiary center in Lithuania between the years 2003 and 2005. Eur J Pediatr. 2011;170(10):1293-303.

Kinsey VE, Jacobus JT, Hemphill F. Retrolental fibroplasia: a cooperative study of retrolental fibroplasia and the use of oxygen. Arch Ophthalmol. 1956;56:481-543.

Kong L, Fry M, Al-Samarraie M, Gilbert C, Steinkuller PG. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J AAPOS. 2012;16(6):501-7.

Markestad T, Kaaresen PI, Ronnestad A, Reigstad H, Lossius K, Medbø S, et al. Early death, morbidity, and need for treatment among extremely premature infants. Pediatr. 2005;115(5):1289-98.

Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Incidence and early course of retinopathy of prematurity. Ophthalmol. 1991;98(11):1628-40.

Patz A, Hoeck LE, de la Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. 1. Nursery observations. Am J Ophthalmol. 1952;35:1248-53.